Editorial
doi: 10.1056/NEJMe048003.
Prostate cancers in men with low PSA levels--must we find them?
- PMID: 15163780
- PMCID: PMC3474980
- DOI: 10.1056/NEJMe048003
Item in Clipboard
Editorial
Prostate cancers in men with low PSA levels--must we find them?
N Engl J Med.
.
No abstract available
Comment on
-
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.N Engl J Med. 2004 May 27;350(22):2239-46. doi: 10.1056/NEJMoa031918. N Engl J Med. 2004. PMID: 15163773 Clinical Trial.
Similar articles
-
Significance of serum free prostate specific antigen in the screening of prostate cancer.J Urol. 1996 Dec;156(6):1964-8. J Urol. 1996. PMID: 8911366 Review.
-
Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.JAMA. 1997 May 14;277(18):1452-5. JAMA. 1997. PMID: 9145717
-
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).Urology. 2004 Feb;63(2):309-13; discussion 313-5. doi: 10.1016/j.urology.2003.09.083. Urology. 2004. PMID: 14972478
-
Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.Eur Urol. 2008 May;53(5):901-8. doi: 10.1016/j.eururo.2008.01.048. Epub 2008 Jan 28. Eur Urol. 2008. PMID: 18262712 Clinical Trial.
-
Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.Urology. 2009 May;73(5 Suppl):S11-20. doi: 10.1016/j.urology.2009.02.016. Urology. 2009. PMID: 19375622 Review.
Cited by
-
Application of H2N-Fe3O4 Nanoparticles for Prostate Cancer Magnetic Resonance Imaging in an Animal Model.Int J Mol Sci. 2024 Sep 26;25(19):10334. doi: 10.3390/ijms251910334. Int J Mol Sci. 2024. PMID: 39408664 Free PMC article.
-
Prevalence and potential predictors of incidental prostate Cancer in patients undergoing surgery for Benign Prostatic obstruction: a retrospective study in the MRI era.World J Urol. 2024 Aug 14;42(1):485. doi: 10.1007/s00345-024-05171-2. World J Urol. 2024. PMID: 39143371
-
Preliminary study on miRNA in prostate cancer.World J Surg Oncol. 2023 Aug 29;21(1):270. doi: 10.1186/s12957-023-03151-1. World J Surg Oncol. 2023. PMID: 37641123 Free PMC article.
-
Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells.Cancer Med. 2023 Apr;12(8):9116-9127. doi: 10.1002/cam4.5649. Epub 2023 Jan 30. Cancer Med. 2023. PMID: 36718027 Free PMC article.
-
Biomarkers for prostate cancer detection and risk stratification.Ther Adv Urol. 2022 Jun 14;14:17562872221103988. doi: 10.1177/17562872221103988. eCollection 2022 Jan-Dec. Ther Adv Urol. 2022. PMID: 35719272 Free PMC article. Review.
References
-
- Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000;11:167–70. - PubMed
-
- Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer. II. Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999;91:1025–32. - PubMed
-
- Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 2003;97:1507–16. - PubMed
-
- Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level of ≤4. 0 ng per milliliter. N Engl J Med. 2004;350:2239–46. - PubMed
-
- Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 1990;143:742–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
